In Vitro Potency of CXA-101, a Novel Cephalosporin, against Pseudomonas aeruginosa Displaying Various Resistance Phenotypes, Including Multidrug Resistance

被引：38

作者：

Bulik, Catharine C. ^{[1
]}

Christensen, Henry ^{[1
]}

Nicolau, David P. ^{[1
]}

机构：

[1] Hartford Hosp, Ctr Antiinfect Res & Dev, FCCP, FIDSA, Hartford, CT 06102 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2010年 / 54卷 / 01期

关键词：

BETA-LACTAMASE; FR264205;

D O I：

10.1128/AAC.00912-09

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We describe the activity of a novel cephalosporin, CXA-101 (FR26 4205), against a panel of highly resistant Pseudomonas aeruginosa isolates collected from U. S. hospitals. CXA-101 demonstrated increased potency against this population of resistant isolates, with activity that is 4- to 10-fold higher than that of comparator agents in each phenotypic category. The addition of tazobactam did not improve its activity. CXA-101 appears to be a promising addition to the category of antipseudomonal beta-lactams.

引用

页码：557 / 559

页数：3

共 13 条

[1] Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. [J].

Castanheira, Mariana ;

Jones, Ronald N. ;

Livermore, David M. .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2009, 63 (04) :426-433

[2]

Clinical and Laboratory Standards Institute, 2008, CLSI PUBL

[3] Comparison of 2002-2006 OPTAMA Programs for US Hospitals: Focus on Gram-Negative Resistance [J].

Crandon, Jared L. ;

Kuti, Joseph L. ;

Jones, Ronald N. ;

Nicolau, David P. .

ANNALS OF PHARMACOTHERAPY, 2009, 43 (02) :220-227

[4]

EAGYE KJ, CLIN THER IN PRESS

[5] Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002 [J].

Flamm, RK ;

Weaver, MK ;

Thornsberry, C ;

Jones, ME ;

Karlowsky, JA ;

Sahm, DF .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (07) :2431-2436

[6] Activity of cephalosporin CXA-101 (FR264205) and comparators against extended-spectrum-β-lactamase-producing Pseudomonas aeruginosa [J].

Giske, Christian G. ;

Ge, James ;

Nordmann, Patrice .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (02) :430-431

[7] Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance [J].

Jones, Ronald N. ;

Kirby, Jeffrey T. ;

Rhomberg, Paul R. .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2008, 61 (02) :203-213

[8] Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates [J].

Livermore, David M. ;

Mushtaq, Shazad ;

Ge, Yigong ;

Warner, Marina .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2009, 34 (05) :402-406

[9] The current state of multidrug-resistant gram-negative bacilli in north America [J].

Nicasio, Anthony M. ;

Kuti, Joseph L. ;

Nicolau, David P. .

PHARMACOTHERAPY, 2008, 28 (02) :235-249

[10] Extended-Spectrum Cephalosporinases in Pseudomonas aeruginosa [J].

Rodriguez-Martinez, Jose-Manuel ;

Poirel, Laurent ;

Nordmann, Patrice .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (05) :1766-1771

← 1 2 →